AIM ImmunoTech (AIM) CEO converts Series G preferred into 25,000 common shares

Rhea-AI Filing Summary

AIM ImmunoTech Inc. CEO and President Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. The preferred stock position was reduced to zero, and his directly held common stock increased to 63,922 shares following the transaction.

Insider Trade Summary

25 shares exercised/converted

Mixed 2 txns

Insider Equels Thomas K

Role CEO & President

Type	Security	Shares	Price	Value
Conversion	Series G Convertible Preferred Stock	25	$0.00	--
Conversion	Common stock	25,000	$0.00	--

Holdings After Transaction: Series G Convertible Preferred Stock — 0 shares (Direct); Common stock — 63,922 shares (Direct)

Footnotes (1)

1. The Preferred shares are convertible into common stock at a rate of 1,000 shares of common stock per whole perferred share, effectively $1.00 per share of common stock. None

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Equels Thomas K

(Last) (First) (Middle)

2117 SOUTHWEST HIGHWAY 484

(Street)

OCALA, FL 34473

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AIM ImmunoTech Inc. [ AIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	03/12/2026		C		25,000	A	$0	63,922	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series G Convertible Preferred Stock	(1)	03/12/2026		C			25	03/06/2026	(2)	common stock	25,000	$0(1)	0	D

Explanation of Responses:

1. The Preferred shares are convertible into common stock at a rate of 1,000 shares of common stock per whole perferred share, effectively $1.00 per share of common stock.

2. None

	/s/ Thomas K Equels	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AIM (AIM) report for Thomas K. Equels?

AIM ImmunoTech reported that CEO Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. This was a non-cash derivative conversion, not an open-market purchase or sale, and increased his directly held common shares.

How many AIM (AIM) common shares did the CEO acquire in this Form 4?

Thomas K. Equels acquired 25,000 shares of AIM ImmunoTech common stock through conversion of Series G Convertible Preferred Stock. The conversion exchanged 25 preferred shares into common shares, increasing his direct common stock holdings as disclosed in the Form 4 filing.

What are Thomas K. Equels’ AIM (AIM) common stock holdings after the transaction?

After the reported conversion, Thomas K. Equels directly holds 63,922 shares of AIM ImmunoTech common stock. This total reflects the addition of 25,000 shares received from converting his Series G Convertible Preferred Stock into common shares on the reported transaction date.

What type of security did the AIM (AIM) CEO convert into common stock?

The CEO converted Series G Convertible Preferred Stock into common stock. Specifically, 25 preferred shares were converted, eliminating his remaining preferred position and resulting in issuance of 25,000 AIM ImmunoTech common shares as detailed in the Form 4 transaction records.

Was the AIM (AIM) CEO’s Form 4 transaction a market buy or sell?

The Form 4 transaction was neither a market buy nor a market sale. It was a derivative conversion, where Series G Convertible Preferred Stock was converted into 25,000 shares of common stock at no reported cash price per share in the transaction table.

What conversion terms are disclosed for AIM (AIM) Series G Preferred shares?

Footnotes state each whole Series G Convertible Preferred share is convertible into 1,000 shares of common stock, effectively equating to $1.00 per share of common stock. In this filing, 25 preferred shares converted into 25,000 AIM ImmunoTech common shares under those terms.